申请人:Schering Corporation
公开号:US05219886A1
公开(公告)日:1993-06-15
Novel mercapto-acylamino acids of the formula ##STR1## wherein Q is hydrogen or R.sup.7 CO--; R.sup.1 is lower alkyl, cyclolower alkyl, aryl or heteroaryl; R.sup.2 is hydrogen; lower alkyl; cyclolower alkyl; lower alkyl substituted with hydroxy, lower alkoxy, mercapto, lower alkylthio, aryl or heteroaryl; aryl; or heteroaryl; R.sup.3 is --OR.sup.5 or --NR.sup.5 R.sup.6 ; R.sup.4 and R.sup.9 are independently --(CH.sub.2).sub.q R.sup.8, provided that when R.sup.4 and R.sup.9 are both hydrogen, R.sup.2 is biphenylyl, phenoxyphenyl, phenylthiophenyl, naphthyl, heteroaryl, or lower alkyl substituted with hydroxy, lower alkoxy, mercapto or lower alkylthio; R.sup.5 and R.sup.6 are independently selected from the group consisting of hydrogen, lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl and aryl lower alkyl, or R.sup.5 and R.sup.6 together with the nitrogen to which they are attached form a 5-7 membered ring; R.sup.7 is hydrogen, lower alkyl or aryl; R.sup.8 is hydrogen, hydroxy, lower alkoxy, mercapto, lower alkylthio, aryl or heteroaryl; n is 1 or 2; p is 0 or 1; q is 0, 1 or 2; and t is 0 or 1; and the pharmaceutically acceptable salts thereof useful in the treatment of cardiovascular disorders and pain conditions and combinations of mercapto-acrylamino acids and atrial natriuretic factors or angiotensin converting enzyme inhibitors useful for treating cardiovascular disorders are disclosed.
本发明涉及一种新型的巯基-酰胺酸,其化学式为:##STR1##其中,Q为氢或R.sup.7CO-;R.sup.1为较低烷基、环较低烷基、芳基或杂环芳基;R.sup.2为氢、较低烷基、环较低烷基、较低烷基取代的羟基、较低烷氧基、巯基、较低烷基硫代基、芳基或杂环芳基、芳基或杂环芳基;R.sup.3为--OR.sup.5或--NR.sup.5R.sup.6;R.sup.4和R.sup.9分别为--(CH.sub.2).sub.qR.sup.8,但当R.sup.4和R.sup.9均为氢时,R.sup.2为联苯基、苯氧基苯基、苯基硫苯基、萘基、杂环芳基或取代有羟基、较低烷氧基、巯基或较低烷基硫代基的较低烷基;R.sup.5和R.sup.6独立地选自羟基较低烷基、较低烷氧基较低烷基、较低烷基硫代基较低烷基和芳基较低烷基的群,或者R.sup.5和R.sup.6与它们连接的氮一起形成5-7成员环;R.sup.7为氢、较低烷基或芳基;R.sup.8为氢、羟基、较低烷氧基、巯基、较低烷基硫代基、芳基或杂环芳基;n为1或2;p为0或1;q为0、1或2;t为0或1;以及其药学上可接受的盐。该巯基-酰胺酸用于治疗心血管疾病和疼痛症状,以及巯基-丙烯酰胺酸和心房利钠肽因子或血管紧张素转化酶抑制剂的组合物,用于治疗心血管疾病。